Navigation Links
Solta Medical, Inc. Announces First Quarter 2009 Results Release Date and Conference Call
Date:4/27/2009

and sun damaged skin. Since 2002, over one million Thermage and Fraxel procedures have been performed in nearly 80 countries. Thermage and Fraxel are the perfect complement for any aesthetic practice. For more information about Solta Medical, call 1-877-782-2286 or log on to www.Solta.com.

    Contact Information:

    Jack Glenn
    Chief Financial Officer
    510-786-6890

    Investor Contacts:
    Doug Sherk/Jenifer Kirtland
    EVC Group
    415-896-6820
    jkirtland@evcgroup.com


'/>"/>
SOURCE Solta Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Thermage, Inc. Announces Name Change to Solta Medical, Inc.
2. Video: Solta Medical Introduces Advanced Thermage Body Tip 16.0 for Faster Body Shaping and Contouring Treatments
3. Solta Medical, Inc. Announces Preliminary Financial Results for the Fourth Quarter of 2008
4. Solta Medical Reports Fourth Quarter and Full Year 2008 Results
5. Solta Medical, Inc. Announces State-of-the-Art Aesthetic Center
6. Solta Medical, Inc. Secures $9M Credit Facility from Silicon Valley Bank
7. Solta Medical Presents Expert Roundtable about Thermage(R) and Fraxel(R) Combination Treatments at ASLMS Annual Meeting
8. Medical, technological advances prompt updating of nuclear medicine technologists scope of practice
9. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
10. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
11. Thermage, Inc. Announces Distribution Agreement With Eclipse Medical, Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... The Dawn Greene Hospice, a 10-bed facility located ... on the Upper East Side, was officially dedicated and blessed ... Eminence Timothy Michael Cardinal Dolan. , Thomas J. Fahey, Jr., ... a member of the ArchCare Board of Trustees, presided over ... executive director of MMW, and Christina McInerney, president and CEO ...
(Date:2/27/2015)... FACE Skincare~Medical~Wellness, a multiaward-winning leader in bringing ... to take fifteen years off of an individual’s ... treatment introduced that is the first and only ... lines and wrinkles on the Décolleté. This new ... the stubborn vertical lines between the upper breast ...
(Date:2/27/2015)... Mediaplanet today announces the launch of its second cross-platform ... bring blood health and cancer awareness to the forefront ... edition go beyond the concept of these insidious diseases ... and technological strides needed to develop new solutions and ... every 3 minutes one person in the United ...
(Date:2/27/2015)... February 27, 2015 Glidewell Laboratories, ... the launch of its CloudPoint™ family ... digital production of monolithic zirconia crowns & bridges, ... of providing the CAD/CAM-produced restorations that doctors demand. ... through which cases can be scanned, managed and ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 ... who have suffered from injuries or diseases affecting ... team of physicians are located throughout Southern California, ... medical procedures to treat conditions related to the ... Dr. Edwin M. Ashley are board-certified and fully ...
Breaking Medicine News(10 mins):Health News:The Dawn Greene Hospice Is Officially Dedicated 2Health News:The Dawn Greene Hospice Is Officially Dedicated 3Health News:Face Skincare Announces New Combination Therapy 2Health News:Know Your Blood: Raising Awareness through Mediaplanet’s “Blood Health” Campaign 2Health News:Glidewell Laboratories Announces Release of CloudPoint™ FastScan™ and FastDesign™ 2Health News:Glidewell Laboratories Announces Release of CloudPoint™ FastScan™ and FastDesign™ 3Health News:Healthpointe is Now Performing Arthroscopic Surgery Techniques for Elbow, Hand and Wrist Injuries and Diseases, such as certain Ganglion Cysts 2
... Conn, Nov. 20 Purdue Pharma L.P. and Mundipharma ... into a global strategic alliance with Infinity Pharmaceuticals, Inc. ... discovery and early clinical programs in the areas of ... , The alliance will focus on ...
... year, the American Pain,Society (APS), http://www.ampainsoc.org , will ... Clinical Centers of Excellence in Pain,Management Awards Program. ... The Clinical Centers ... of healthcare professionals who are satisfying,unmet critical needs in ...
... KANSAS CITY, Mo., Nov. 20 Does this look familiar?,Bailouts, ... stores are ghost towns, and everyone is uninsured without a,retirement ... and,find anything to be optimistic about. , ... We are facing tough economic ...
... Chemotherapy figures alone may differ by almost $37,000 per ... -- The cost of treating colorectal cancer can vary ... To reach that conclusion, researchers compared the eight most ... 400 patients at 115 ambulatory care centers across the ...
... Elizabeth T. H. (Terry) Fontham, MPH, DrPH, Dean of the LSU ... the first non-physician elected national President of the American Cancer Society ... National Assembly Meeting on November 20, 2008 in New York City. ... female to serve as president in the organization,s 96-year history., ...
... Polling of Americans and Industry Thought Leaders Finds Competing ... Nov. 20 /PRNewswire-USNewswire/ -- Three-quarters of Americans ... major health care reform legislation to be passed in ... findings of new polling released today by the National ...
Cached Medicine News:Health News:Purdue Pharma L.P. Announces a Global Strategic Alliance With Infinity Pharmaceuticals to Advance Discovery and Development Programs in Oncology and Neuropathic Pain 2Health News:American Pain Society Accepting Applications for Clinical Centers of Excellence in Pain Management Awards 2Health News:Don't Let Economic Struggles Destroy Your Teeth 2Health News:Colorectal Cancer Treatment Costs Vary Widely 2Health News:LSUHSC's Fontham makes history 2Health News:LSUHSC's Fontham makes history 3Health News:Three-Quarters of Americans and Industry Leaders Want Health Care Reform in President-elect Obama's First Term 2Health News:Three-Quarters of Americans and Industry Leaders Want Health Care Reform in President-elect Obama's First Term 3Health News:Three-Quarters of Americans and Industry Leaders Want Health Care Reform in President-elect Obama's First Term 4Health News:Three-Quarters of Americans and Industry Leaders Want Health Care Reform in President-elect Obama's First Term 5Health News:Three-Quarters of Americans and Industry Leaders Want Health Care Reform in President-elect Obama's First Term 6
(Date:2/27/2015)... 27, 2015 ... für kongestive Herzinsuffizienz (CHF) in seiner ersten ...     Die israelische ... Herzüberwachungssystem für Patienten mit kongestiver Herzinsuffizienz (CHF) ... ein Finanzierungsvorhaben über 5 Mio. USD abgeschlossen ...
(Date:2/27/2015)... Feb. 27, 2015  Two mass spectrometry ... applications as their effectiveness is established, according ...  Kalorama Information says that while mass spectrometry ... powerful tool in proteomic biomarker discovery and ... its traditional techniques has struggled to elucidate ...
(Date:2/26/2015)... , Feb. 26, 2015  AbbVie (NYSE: ... of studies in its neuroscience and oncology development ... 67 th American Academy of Neurology annual ... from April 18-25. The accepted abstracts feature results ... addition to investigational treatments in AbbVie,s pipeline. Presentations ...
Breaking Medicine Technology:Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7
... Shire plc (LSE: SHP, Nasdaq: SHPGY ), ... a 5-aminosalicylic acid (5-ASA) persistency analysis entitled, "Twelve-month Persistence ... Database," at Digestive Disease Week, on May 31, 2009. ... continuing patients, 20 percent of Lialda patients were continually ...
... Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN ... 1 safety and efficacy results following administration of ... with high-risk genomic factors and relapsed or refractory ... proprietary anti-CD37 Small Modular ImmunoPharmaceutical (SMIP(TM)) product candidate. ...
Cached Medicine Technology:Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week 2Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week 3Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week 4Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week 5Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL) 2Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL) 3Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL) 4Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL) 5